Who Paid My Doc
Caleb Lusk
Addiction Medicine San Pedro, CA Medical Doctor
NPI 1386149912 CMS profile 9845463
593 W 6Th St, San Pedro, CA 90731
General payments
$7,338
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Caleb Lusk of San Pedro, CA is reported in the CMS Open Payments database as having received $7,338 across 106 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,371 | 47 | |
| 2024 | General | $920 | 36 | |
| 2023 | General | $4,997 | 21 | |
| 2021 | General | $51 | 2 |
Beside peers
- Caleb Lusk
- Addiction Medicine median
- Middle half of Addiction Medicine
- National median
In program year 2025, general payments to Caleb Lusk were reported at $1,371. Among 306 Addiction Medicine profiles paid that year, the median was $147 and the middle half received between $46 and $381.
Show as a table
| Year | Caleb Lusk | Addiction Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $96 | $32–$265 | $163 |
| 2020 | $0 | $53 | $20–$176 | $114 |
| 2021 | $51 | $86 | $24–$265 | $132 |
| 2022 | $0 | $89 | $27–$330 | $149 |
| 2023 | $4,997 | $102 | $39–$363 | $160 |
| 2024 | $920 | $110 | $38–$311 | $164 |
| 2025 | $1,371 | $147 | $46–$381 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
212
Drug cost
$10,565
Branded share of claims
10.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Vascepa Icosapent Ethyl | Brand | 11 | $5,399 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 11 | $3,434 | |
| Atorvastatin Calcium | Generic | 57 | $521 | |
| Diclofenac Sodium | Generic | 13 | $298 | |
| Metformin Hcl | Generic | 25 | $206 | |
| Losartan Potassium | Generic | 13 | $190 | |
| Lisinopril | Generic | 21 | $142 | |
| Fluticasone Propionate | Generic | 16 | $120 | |
| Tamsulosin Hcl | Generic | 11 | $114 | |
| Amlodipine Besylate | Generic | 17 | $83 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 14 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| MAVYRET |
|
$206 | — | — |
| CABENUVA |
|
$65 | — | — |
| Wegovy |
|
$45 | — | — |
| SUBLOCADE |
|
$41 | — | — |
| APRETUDE |
|
$35 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 14 in the dashboard with a free accountRecords
106 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Medicine in California
Tipu Khan
Addiction Medicine · Ventura, CA
Matthew Torrington
Addiction Medicine · Culver City, CA
Abraham Malkin
Addiction Medicine · Los Angeles, CA
Francisco Pardo
Addiction Medicine · San Diego, CA
John Bennetts
Addiction Medicine · Monterey, CA
Jonathan Watson
Addiction Medicine · Santa Ana, CA
Related records
Addiction Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.